798 Shares in Axon Enterprise, Inc. (NASDAQ:AXON) Bought by Brookstone Capital Management

Brookstone Capital Management bought a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 798 shares of the biotechnology company’s stock, valued at approximately $206,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Westfield Capital Management Co. LP grew its stake in shares of Axon Enterprise by 184.3% during the third quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock worth $138,535,000 after purchasing an additional 451,350 shares in the last quarter. BKM Wealth Management LLC acquired a new position in shares of Axon Enterprise during the fourth quarter worth $32,000. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Axon Enterprise by 0.3% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 147,345 shares of the biotechnology company’s stock valued at $29,320,000 after acquiring an additional 495 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Axon Enterprise by 11.5% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 63,778 shares of the biotechnology company’s stock valued at $12,691,000 after acquiring an additional 6,585 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Axon Enterprise by 10.1% in the third quarter. Ameriprise Financial Inc. now owns 379,286 shares of the biotechnology company’s stock valued at $75,474,000 after acquiring an additional 34,728 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Trading Down 1.1 %

NASDAQ AXON opened at $315.64 on Thursday. The stock has a market capitalization of $23.82 billion, a P/E ratio of 137.24 and a beta of 0.93. Axon Enterprise, Inc. has a 52-week low of $175.37 and a 52-week high of $325.63. The firm has a 50-day moving average price of $283.44 and a 200 day moving average price of $245.70. The company has a quick ratio of 2.66, a current ratio of 3.00 and a debt-to-equity ratio of 0.42.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.29. The firm had revenue of $432.14 million during the quarter, compared to analysts’ expectations of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. Equities research analysts expect that Axon Enterprise, Inc. will post 2.43 EPS for the current year.

Insider Buying and Selling

In related news, President Joshua Isner sold 35,400 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $251.68, for a total transaction of $8,909,472.00. Following the completion of the transaction, the president now directly owns 309,564 shares of the company’s stock, valued at $77,911,067.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

AXON has been the subject of a number of research reports. Morgan Stanley boosted their price target on shares of Axon Enterprise from $250.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. TheStreet cut shares of Axon Enterprise from a “b” rating to a “c+” rating in a research report on Tuesday, February 27th. Argus initiated coverage on shares of Axon Enterprise in a research report on Wednesday, March 13th. They issued a “buy” rating and a $380.00 price target for the company. Needham & Company LLC boosted their price target on shares of Axon Enterprise from $240.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. Finally, StockNews.com cut shares of Axon Enterprise from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and an average price target of $301.73.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.